RU2018125034A3 - - Google Patents

Download PDF

Info

Publication number: RU2018125034A3
Authority: RU; Russia

Application number

RU2018125034A

Other languages

Russian (ru)

Other versions

RU2018125034A (en

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-11

Filing date

2016-12-09

Publication date

2020-04-15

2015-12-11 Priority claimed from US14/966,759 external-priority patent/US20160095908A1/en

2016-12-09 Application filed filed Critical

2020-01-13 Publication of RU2018125034A publication Critical patent/RU2018125034A/en

2020-04-15 Publication of RU2018125034A3 publication Critical patent/RU2018125034A3/ru

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

RU2018125034A 2015-12-11 2016-12-09 BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR RU2018125034A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US14/966,759 US20160095908A1 (en)	2005-06-14	2015-12-11	Botulinum Toxin for Primary Disorders of Mood and Affect using Neurotransmitter CNS imaging Studies
US14/966,759		2015-12-11
PCT/US2016/065898 WO2017100624A1 (en)	2015-12-11	2016-12-09	Botulinum toxin for primary disorders of mood and affect using neurotransmitter

Publications (2)

Publication Number	Publication Date
RU2018125034A RU2018125034A (en)	2020-01-13
RU2018125034A3 true RU2018125034A3 (en)	2020-04-15

Family

ID=59013649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RU2018125034A RU2018125034A (en)	2015-12-11	2016-12-09	BOTULOTOXIN FOR THE TREATMENT OF PRIMARY DISORDERS OF MOOD AND AFFECT WITH THE PARTICIPATION OF A NEUROMEDIATOR

Country Status (13)

Country	Link
EP (1)	EP3386538A4 (en)
JP (1)	JP2019504824A (en)
KR (1)	KR20180093983A (en)
CN (1)	CN109069609A (en)
AU (1)	AU2016366428A1 (en)
BR (1)	BR112018011663A2 (en)
CA (1)	CA3007816A1 (en)
CO (1)	CO2018007096A2 (en)
IL (1)	IL259825A (en)
MX (1)	MX2018007105A (en)
RU (1)	RU2018125034A (en)
SG (1)	SG11201804840SA (en)
WO (1)	WO2017100624A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2021137667A1 (en) *	2019-12-30	2021-07-08	주식회사 에이티지씨	Composition for treating parkinson's disease containing botulinum neurotoxin, and method for treating parkinson's disease using same
CN114384185A (en) *	2022-01-20	2022-04-22	北京航空航天大学	Application of reagent for detecting gamma-aminobutyric acid content in preparation of kit for diagnosing venous outflow obstruction diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8734810B2 (en) *	2003-10-29	2014-05-27	Allergan, Inc.	Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609112B2 (en) *	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US20070264373A1 (en) *	2004-01-26	2007-11-15	Ian Carroll	Toxin Induced Sympathectomy
US20100266638A1 (en) *	2004-02-26	2010-10-21	Allergan, Inc.	Headache treatment method
US7655244B2 (en) *	2005-02-01	2010-02-02	Allergan, Inc.	Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US8926991B2 (en) *	2005-06-14	2015-01-06	Botulinum Toxin Research Associates, Inc.	Botulinum toxin and the treatment of primary disorders of mood and affect
US20070218084A1 (en) *	2005-12-30	2007-09-20	Fondazione Pierfranco E Luisa Mariani- Onlus	Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
JP2010501566A (en) *	2006-08-21	2010-01-21	プレクサファーマシューティカルズ，インコーポレイテッド	Multitransmitter transporter inhibitors for use in the treatment of central nervous system disorders
WO2010013495A1 (en) *	2008-07-31	2010-02-04	財団法人化学及血清療法研究所	Pharmaceutical composition containing highly purified botulinum neurotoxin therapeutic agent as active ingredient, and use thereof
US9393291B2 (en) *	2012-04-12	2016-07-19	Botulinum Toxin Research Associates, Inc.	Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9480731B2 (en) *	2013-12-12	2016-11-01	Medy-Tox, Inc.	Long lasting effect of new botulinum toxin formulations

2016
- 2016-12-09 CA CA3007816A patent/CA3007816A1/en not_active Abandoned
- 2016-12-09 AU AU2016366428A patent/AU2016366428A1/en not_active Abandoned
- 2016-12-09 MX MX2018007105A patent/MX2018007105A/en unknown
- 2016-12-09 CN CN201680079413.0A patent/CN109069609A/en active Pending
- 2016-12-09 SG SG11201804840SA patent/SG11201804840SA/en unknown
- 2016-12-09 EP EP16873950.6A patent/EP3386538A4/en not_active Withdrawn
- 2016-12-09 BR BR112018011663A patent/BR112018011663A2/en not_active IP Right Cessation
- 2016-12-09 JP JP2018529573A patent/JP2019504824A/en active Pending
- 2016-12-09 WO PCT/US2016/065898 patent/WO2017100624A1/en active Application Filing
- 2016-12-09 RU RU2018125034A patent/RU2018125034A/en not_active Application Discontinuation
- 2016-12-09 KR KR1020187019212A patent/KR20180093983A/en unknown
2018
- 2018-06-05 IL IL259825A patent/IL259825A/en unknown
- 2018-07-06 CO CONC2018/0007096A patent/CO2018007096A2/en unknown

Also Published As

Publication number	Publication date
JP2019504824A (en)	2019-02-21
WO2017100624A1 (en)	2017-06-15
KR20180093983A (en)	2018-08-22
IL259825A (en)	2018-07-31
CA3007816A1 (en)	2017-06-15
CO2018007096A2 (en)	2018-11-22
RU2018125034A (en)	2020-01-13
CN109069609A (en)	2018-12-21
SG11201804840SA (en)	2018-07-30
MX2018007105A (en)	2018-09-07
BR112018011663A2 (en)	2018-12-04
AU2016366428A1 (en)	2018-06-28
EP3386538A1 (en)	2018-10-17
EP3386538A4 (en)	2019-07-17

Publication	Publication Date	Title
BE2015C047I2 (en)	2022-08-10
BE2015C044I2 (en)	2023-08-31
BR0000126B1 (en)	2015-07-14
BR0000695B1 (en)	2015-07-21
BR0000763F1 (en)	2015-09-15
BR0001536B1 (en)	2015-09-29
BR0001684B1 (en)	2015-04-22
BR0001810B1 (en)	2015-06-23
BR0002033B1 (en)	2015-06-09
BR0002402B1 (en)	2015-08-11
BR0002435B1 (en)	2015-05-19
BR0002694B1 (en)	2015-08-04
BR0002802B1 (en)	2015-03-31
BR0002874B1 (en)	2015-09-01
BR0003166B1 (en)	2015-08-25
BR0003189B1 (en)	2015-03-24
BR0003208B1 (en)	2015-03-17
BR0003401B1 (en)	2015-08-25
BR0003686B1 (en)	2015-08-18
BR0003746B1 (en)	2015-08-25
BR0003751B1 (en)	2015-08-11
BR0003928B1 (en)	2015-09-15
BR0004687B1 (en)	2015-05-05
BR0005041B1 (en)	2015-08-11
BR0005085B1 (en)	2015-06-09

Legal Events

Date	Code	Title	Description
2021-12-10	FA92	Acknowledgement of application withdrawn (lack of supplementary materials submitted)	Effective date: 20211203